For example, peptide YY and glucagon-like peptide-1 (GLP-1) are released in response to food intake and influence appetite and glucose metabolism, with receptors in the brain that affect satiety and cognitive function [43]
Patients should still discuss appropriateness, safety, and monitoring with a qualified healthcare professional before use
Source: JAMA Health Forum Repost to share with colleagues navigating GLP-1 coverage decisions Follow me for more on employer pharmacy benefits (Bryce Platt, PharmD) As with most things in healthcare spend, this is complicated, however, I would be quite surprised if more widespread availabity would not lead to substantial cost savings over time (not necessarily for the plans, as many of those savings may be later and for Medicare etc.) Prices have continued to drop from 2025 numbers and will likely continue with more competition and more users, and, as with all medicines, costs will drop quite a bit as the first generics start coming, so this is not a cost forever, it is for a few years
doi: 10.1016/j.diabres.2008.09.041 Summary Keywords GLP-1r, GCGR, TB001, allograft fibrosis, lipid metabolism Citation Peng L, Lai W, Yu S, Li Q, Jiang X and Chen G (2025) GLP-1 and glucagon receptor dual agonism ameliorates kidney allograft fibrosis by improving lipid metabolism
